Disclaimer: This site has been first put up 15 years ago. Since then I would probably do a couple things differently, but because I've noticed this site had been linked from news outlets, PhD theses and peer rewieved papers and because I really hate the concept of "digital dark age" I've decided to put it back up. There's no chance it can produce any harm now.
| Identifier: | 03ANKARA6068 |
|---|---|
| Wikileaks: | View 03ANKARA6068 at Wikileaks.org |
| Origin: | Embassy Ankara |
| Created: | 2003-09-26 13:03:00 |
| Classification: | UNCLASSIFIED//FOR OFFICIAL USE ONLY |
| Tags: | ETRD KIPR TU |
| Redacted: | This cable was not redacted by Wikileaks. |
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS ANKARA 006068 SIPDIS TREASURY FOR OASIA STATE FOR EB/TPP/MTA/IPC DEPT PASS USTR FOR LERRION/MWU USDOC FOR ITA/MAC/DDEFALCO SENSITIVE E.O. 12958: N/A TAGS: ETRD, KIPR, TU SUBJECT: Proposal for a Joint Demarche with EU on Intellectual Property Issues (Action Request) Ref: State 5808 and previous 1. (U) This cable contains an action request in para 4. 2. (SBU) In recent years, the USG has pressed Turkey to improve protection of intellectual property rights, particularly for pharmaceuticals manufacturers, but with limited results thus far. Copyright and trademark holders continue to face high levels of piracy and counterfeiting. U.S. pharmaceuticals companies are hurt by lack of data exclusivity and price discrimination against imported drugs. Furthermore, there has been some discussion of weakening patent protection for pharmaceuticals (reftel). 3. (SBU) The EU and European companies have similar views on IPR problems in Turkey. We understand that the European pharmaceutical association is preparing a sharply critical report on Turkey and may press for a WTO case. Data exclusivity is a key common concern, as it is both a WTO and EU customs union requirement. We believe that the GOT will give added weight to these issues to the extent that it perceives them to become a serious obstacle to EU accession. 4. (SBU) Embassy proposes a joint U.S. - EU demarche to the Turks on IPR, specifically issues facing the pharmaceutical industry, and requests that Washington agencies provide appropriate instructions. Edelman
Latest source of this page is cablebrowser-2, released 2011-10-04